These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33351204)

  • 1. Evolution of antigen-specific immune responses in cutaneous leishmaniasis patients.
    Mohammadi AM; Duthie MS; Reed SG; Javadi A; Khamesipour A
    Parasite Immunol; 2021 Apr; 43(4):e12814. PubMed ID: 33351204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients.
    Carvalho LP; Passos S; Dutra WO; Soto M; Alonso C; Gollob KJ; Carvalho EM; Ribeiro de Jesus A
    Scand J Immunol; 2005 Apr; 61(4):337-42. PubMed ID: 15853916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.
    Bottrel RL; Dutra WO; Martins FA; Gontijo B; Carvalho E; Barral-Netto M; Barral A; Almeida RP; Mayrink W; Locksley R; Gollob KJ
    Infect Immun; 2001 May; 69(5):3232-9. PubMed ID: 11292745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenicity of
    Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
    Front Immunol; 2018; 9():843. PubMed ID: 29740446
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis.
    Carvalho AM; Magalhães A; Carvalho LP; Bacellar O; Scott P; Carvalho EM
    BMC Infect Dis; 2013 Nov; 13():529. PubMed ID: 24206576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.
    Skeiky YA; Guderian JA; Benson DR; Bacelar O; Carvalho EM; Kubin M; Badaro R; Trinchieri G; Reed SG
    J Exp Med; 1995 Apr; 181(4):1527-37. PubMed ID: 7699334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic and Functional Profiles of Antigen-Specific CD4
    Egui A; Ledesma D; Pérez-Antón E; Montoya A; Gómez I; Robledo SM; Infante JJ; Vélez ID; López MC; Thomas MC
    Front Cell Infect Microbiol; 2018; 8():393. PubMed ID: 30510917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the immune response to Leishmania infantum recombinant antigens.
    de Carvalho LP; Soto M; Jerônimo S; Dondji B; Bacellar O; Luz V; Orge Orge G; Alonso C; Jesus AR; Carvalho EM
    Microbes Infect; 2003 Jan; 5(1):7-12. PubMed ID: 12593967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis.
    Maasho K; Wolday D; Edjigu M; Söderström K; Britton S; Akuffo H
    Clin Exp Immunol; 2001 May; 124(2):255-61. PubMed ID: 11422202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.
    Coler RN; Goto Y; Bogatzki L; Raman V; Reed SG
    Infect Immun; 2007 Sep; 75(9):4648-54. PubMed ID: 17606603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB/c Mice.
    Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A; Dayer MS
    Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):55-64. PubMed ID: 28779346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
    Coler RN; Skeiky YA; Bernards K; Greeson K; Carter D; Cornellison CD; Modabber F; Campos-Neto A; Reed SG
    Infect Immun; 2002 Aug; 70(8):4215-25. PubMed ID: 12117930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.
    Santos DM; Carneiro MW; de Moura TR; Fukutani K; Clarencio J; Soto M; Espuelas S; Brodskyn C; Barral A; Barral-Netto M; de Oliveira CI
    Int J Nanomedicine; 2012; 7():2115-27. PubMed ID: 22619548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response to Leishmania antigen in anthroponotic cutaneous leishmaniasis.
    Ajdary S; Riazi-Rad F; Alimohammadian MH; Pakzad SR
    J Infect; 2009 Aug; 59(2):139-43. PubMed ID: 19560211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major.
    Kemp M; Handman E; Kemp K; Ismail A; Mustafa MD; Kordofani AY; Bendtzen K; Kharazmi A; Theander TG
    FEMS Immunol Med Microbiol; 1998 Mar; 20(3):209-18. PubMed ID: 9566492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccination with a plasmid encoding LACK-TSA fusion against Leishmania major infection in BALB/c mice.
    Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A; Khademi SZ
    Malays J Pathol; 2017 Dec; 39(3):267-275. PubMed ID: 29279589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure.
    Coutinho SG; Oliveira MP; Da-Cruz AM; De Luca PM; Mendonça SC; Bertho AL; Soong L; McMahon-Pratt D
    Exp Parasitol; 1996 Nov; 84(2):144-55. PubMed ID: 8932764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
    Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
    Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
    Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.